Marcel A. Deken

Amsterdam, NH 1082MA, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Journal: Cell reports

Published: May 19, 2026

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.

Journal: Cell reports

Published: May 19, 2025

Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.

Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.

Journal: Leukemia & lymphoma

Published: December 27, 2024

89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.

89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.

Journal: Cancers

Published: September 07, 2023

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Journal: International journal of toxicology

Published: September 05, 2023

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Journal: Molecular cancer therapeutics

Published: August 10, 2023

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors.

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors.

Journal: Immuno-oncology technology

Published: May 26, 2023

Autotaxin Inhibition with IOA-289 Decreases Breast Tumor Growth in Mice Whereas Knockout of Autotaxin in Adipocytes Does Not.

Autotaxin Inhibition with IOA-289 Decreases Breast Tumor Growth in Mice Whereas Knockout of Autotaxin in Adipocytes Does Not.

Journal: Cancers

Published: April 14, 2023

Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial.

Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial.

Journal: Journal of pharmaceutical and biomedical analysis

Published: March 10, 2022

Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery.

Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery.

Journal: European journal of nuclear medicine and molecular imaging

Published: July 08, 2020

Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer.

Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer.

Journal: The British journal of surgery

Published: October 16, 2019

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Journal: International journal of molecular sciences

Published: October 28, 2016

Showing 1-12 of 16

Last Updated: 09/26/2026